Sanofi terminates development of iniparib in NSCLC
The randomized Phase III ECLIPSE trial of iniparib from Sanofi, in squamous Non-Small Cell Lung Cancer (Sq NSCLC) did not meet its primary endpoint. In the study, newly diagnosed, metastatic Sq NSCLC patients treated with iniparib plus chemotherapy did not achieve improvement in overall survival compared to patients who received chemotherapy alone. There were no clinically meaningful differences in the main safety parameters between the two arms. The topline results of a Phase II study of iniparib in platinum-resistant ovarian cancer do not support further development of iniparib in this patient population.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.